Dividend and Recent Updates on Phibro Animal Health: Everything You Need to Know Before the Sep 3, 2025 Ex-Dividend Date

Phibro Animal Health (PAHC) has announced a cash dividend of $0.12 per share, with the ex-dividend date set for Sep 3, 2025. This follows an announcement on Jul 29, 2025, and the dividend will be distributed on Sep 24, 2025. The payout is slightly higher than the average of the last 10 dividend amounts, which stands at $0.11227. The previous dividend was issued on Jun 25, 2025, also at $0.12 per share, and was also a cash dividend. Investors considering a purchase ahead of the ex-dividend date should be aware that Sep 3, 2025, is the last day to buy the stock and be eligible for the upcoming dividend payment. Any purchases after this date will not qualify for the dividend.

Recently, Phibro Animal Health has seen a significant revenue boost, particularly in its Q4 FY2025 results. GAAP revenue surged by 39% to $378.7 million, driven largely by the acquisition of Zoetis’ medicated feed additive business. This acquisition has contributed to a 53% sales growth in the Animal Health segment and a 47% increase in adjusted EBITDA, reflecting strong operational performance. The company has also provided financial guidance for the upcoming period, which, combined with its recent performance, has raised investor optimism.

Over the past week, PAHC’s stock has been underpinned by positive momentum, with shares rising by 37% in the last 30 days and a 79% annual gain. Analysts have noted that the company’s price-to-sales ratio of 1.2x is significantly lower than the industry average, which could be a compelling factor for value-oriented investors. However, this low valuation may also reflect concerns about the company’s future growth potential, as analysts project revenue growth of just 5.8% annually over the next three years—well below the industry’s expected 25% annual expansion.

As of late, PAHC’s stock price surged 17.98% in pre-market trading on Aug 28, 2025, following a price target increase by Morgan Stanley. This move came in the wake of the company’s strong Q4 earnings report and strategic acquisitions, which have positioned Phibro for continued growth in the Animal Health sector. Additionally, institutional investors like Brant Point Investment Management LLC have shown increased confidence in the company by investing $2.22 million in its stock. These developments underscore a growing consensus among investors and analysts that Phibro is on a positive trajectory, despite lingering uncertainties about its long-term growth prospects.

Phibro Animal Health’s ex-dividend date of Sep 3, 2025, marks a critical point for investors aiming to participate in the dividend distribution. Investors should consider the company’s strong recent financial performance, including robust revenue growth and strategic acquisitions, as well as the current valuation metrics, when making investment decisions. The ex-dividend date is the last day for investors to buy the stock and be eligible for the upcoming dividend. Any purchase after this date will not qualify for the dividend of this time.